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The World Health Organization recommendations on
management of common childhood illnesses affect the lives of
millions of children admitted to hospital worldwide. Its latest
guidelines,1 released inMay 2013, continue to recommend rapid
fluid resuscitation for septic shock, even though the only large
controlled trial of this treatment (Fluid Expansion as a
Supportive Treatment (FEAST) found that it increased the risk
of death in African children.2 A subsequent systematic review
of bolus resuscitation in children with shock resulting from
severe infection also did not support its use.3 Failure to take this
evidence into account is not consistent withWHO’s commitment
to systematically and transparently assess evidence using the
GRADE (Grading of Recommendations Assessment,
Development and Evaluation) process when producing
guidelines and could endanger the lives of children.
Evidence on fluid resuscitation
Rapid fluid resuscitation was recommended as a lifesaving
treatment for shock on the basis of a GRADE systematic review
that found weak evidence of benefit (largely expert opinion
based on two paediatric case series at a single tertiary centre).4
It has become a key component of surviving sepsis campaigns
in children and adults4 5 and is widely practised in well resourced
settings. Fluid resuscitation is also being increasingly promoted
in resource poor settings6 7 as part of the WHO endorsed
emergency triage assessment and treatment training.8 This is
despite systematic reviews9 and commentaries highlighting
concerns that these recommendations are not based on research
evidence.10
FEAST was published in 2011. It is the only randomised
controlled trial comparing bolus fluid resuscitation with no
bolus. The study was conducted in six African hospitals without
intensive care facilities in Kenya, Tanzania, and Uganda and
enrolled 3141 children with fever and shock (one or more
features of impaired perfusion with impaired consciousness or
respiratory distress, or both). The study included a prespecified
analysis of subgroups of children with malaria and anaemia, as
these conditions are relevant to resource poor settings. Children
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with gastroenteritis, severe malnutrition, burns, or surgical
conditions were excluded.
Children were randomly assigned to receive rapid resuscitation
with albumin or normal saline boluses (20-40 ml/kg over 1-2
hours) or no bolus (control group). All children received
standard treatments according to their illness, including standard
of care maintenance fluids (mainly 5% dextrose/saline at 2.5-4
ml/kg/h) until able to drink, antibiotics, antimalarials, oxygen,
and transfusion.
The trial was stopped early by the data monitoring committee
because rapid resuscitation resulted in a 45% relative (95%
confidence interval 13% to 86%) increase in 48 hour mortality
compared with controls. The absolute excess in mortality was
3.3% (1.2% to 5.3%). This increase in mortality was seen in
every subgroup, across the age spectrum (3 months-12 years),
and at each of the six centres from three countries in the trial,2
irrespective of the pathogen (malaria, bacterial sepsis, or
anaemia). Further planned analysis showed that although
children given a bolus had a superior shock resolution than those
in the control group, they were more likely to die as a result of
cardiovascular collapse.11
A systematic review published in 2012 assessed the evidence
for bolus fluid resuscitation further and included 13 studies (four
in general shock, four in malaria, four in dengue fever, and one
in severe malnutrition).3 The only study to include a control arm
(no fluid bolus) was FEAST, which drove the results. Overall,
and in subgroups of children with sepsis or malaria, those who
received no fluid bolus had significantly lower mortality at 48
hours (76/1044) compared with those who received saline or
colloid boluses (221/2097, relative risk 0.69, 95% confidence
interval 0.54 to 0.89 for sepsis and 0.64, 0.46 to 0.91 for
malaria).
Problems interpreting FEAST
A serious question raised during the debate about FEAST was
whether the broad criteria used to define shock affected the
applicability of the results since various international guidelines
use a narrower definition of shock, which in turn may influence
how children are managed.12-14 FEAST defined shock as children
with fever and one or more features of impaired perfusion plus
impaired consciousness or respiratory distress, or both. Half of
the children had two or more features. But within this broad
definition we were able to look at subgroups that meet the
narrower criteria used in US andWHOguidelines.5-15We applied
all published definitions of paediatric shock to the FEAST trial
data (table⇓)12 and found that for every definition, bolus
resuscitation resulted in a worse outcome comparedwith control.
The criteria for shock in the WHO guidelines represent the
sickest children, requiring the presence a capillary refilling time
of more than 3 seconds, cold peripheries, a weak pulse, and a
fast pulse. This definition applied to only 65 (2%) of the 3141
children in FEAST. They were a very high risk group,
accounting for about 10% of all deaths in the trial; 24/50 (48%)
of children who received boluses died within 48 hours compared
with 3/15 (20%) of control childrenmeetingWHO criteria12—an
absolute increase in risk of 28% and relative risk of 240%
(P=0.07, two sided Fisher’s exact test). Although the FEAST
trial was not powered to detect differences between arms for
children in theWHO defined shock, a basic principle of clinical
trials is that subgroup results should be interpreted within the
context of the overall trial results, which provide a more reliable
assessment of the effect of the intervention than an analysis
restricted to patients in the subgroup.16 17 The result in the
subgroup is consistent with the overall result.
Concern has also been expressed about the consequences of not
giving bolus fluids to children with moderate hypotension and
severe dehydration. Again, FEAST was not powered to detect
differences in these subgroups, but the results are consistent
with harm from use of bolus resuscitation.12
In children with hypotension (defined in FEAST as systolic
blood pressure 50-75, 60-75, and 70-85mmHg in children aged
<12 months, 1-5 years, and >5 years respectively, in line with
clinical use) there was a trend towards increased mortality in
the bolus arms (absolute difference 9.4%, 95% confidence
interval −2.6% to 21.4%). Severe hypotension is very
uncommon in children, as shown by the very small number of
children (n=29) with this condition who were enrolled in the
FEAST trial; all of these children were randomised to receive
either colloid of saline boluses.2 Of interest, only eight of the
29 children fulfilled the WHO definition of shock and all eight
died.
Overall, severe dehydration without diarrhoea was present in
236 children (7.5%) in FEAST, and we found no evidence that
boluses were of benefit; there were 38/173 (22%) deaths in the
bolus arm versus 8/58 (13.8%) in the control (relative risk 1.59,
95% confidence interval 0.79 to 3.21).11
Change led by FEAST
The FEAST trial was praised for demonstrating how rigorous
clinical research can be done in resource poor settings.
Subsequently, the findings have been widely debated, as they
challenged the primacy of bolus resuscitation as a lifesaving
intervention for paediatric shock in resource limited settings
and raised questions about their use elsewhere. Following
publication of a systematic review of the evidence,3 Médicins
Sans Frontières revised its paediatric shock guideline in March
2012.
A meeting hosted by the Kenyan Paediatric Association in
October 2012 raised concern about WHO’s lack of response to
the FEAST results. Participants, including representatives from
10 countries in sub-Saharan Africa, sent a letter to WHO in
March 2013, stating that they had reviewed the data and were
advocating that their countries revise their guidelines for fluid
management of shock. They requested that WHO do the same.
2013 WHO guidelines in practice
WHO had begun revising its Pocket Book of Hospital Care for
Childrenwhen the FEAST trial results were released. We were
aware of this process and provided additional unpublished data
to the guideline developers when requested. We assumed that
our data would be taken into account in the revision. However,
the 2013 edition continues to recommend a 20 ml/kg bolus of
isotonic crystalloid as fast as possible to any child fulfilling the
WHO definition of shock, with up to two more boluses (that is,
a total of 60 ml/kg) if shock fails to correct. 1 18 This is much
more aggressive treatment than in the FEAST trial, where most
children received a single bolus of 20 ml/kg over one hour.2
For children with suspected malaria or anaemia with shock, the
new WHO guidelines state that “fluid be administered
cautiously, and/or blood transfusion should be given for severe
anaemia,”1 leaving clinicians unclear about the rate and volume
of fluids to give in these two conditions. The guidelines
committee did not consider the speed of resuscitation, only the
choice of fluid.18
We are concerned that, given results of FEAST and their
consistency across subgroups, including in those meeting the
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strict WHO definition of shock, these recommendations might
expose substantial numbers of children to harm.
How many children do these guidelines apply to in Africa?
There are no reliable data on the number of child admissions to
hospital with shock each year in sub-Saharan Africa. We have
previously reported that about 10% of children admitted to
hospital in the coast of Kenya present with shock,19 indicating
that the number would likely run into millions. For every million
hospital admissions with shock, around 20 000 (2%) would be
expected to meet the WHO definition of shock.2 Our subgroup
analysis of the FEAST results suggested bolus was associated
with a relative risk of death of 240% in these children. Treatment
with rapid fluid resuscitation may therefore result in hundreds
or thousands of excess deaths.
Distinguishing between WHO defined shock and other milder
forms of shock is challenging in practice. Accurate measurement
of blood pressure in children requires training to use automated
technologies that are expensive, require frequent maintenance,
and are rarely available. Capillary refill is difficult to measure
accurately and has inherent between and within observer
variation.20 WHO does not give advice on how to manage
children who do not meet its definition of shock, and it is likely
that there will be slippage in the implementation of the
guidelines, as there is in high income countries, with children
who do not meet the strict definition being given rapid fluid
resuscitation. This could expose even more children to the
harmful effects of fluid boluses.
The failure of WHO to take account of the FEAST data is
disappointing and puzzling, particularly given its commitment
to systematic assessment of evidence. Indeed, the pocketbook’s
guidance on managing severe malaria was amended in the light
of a trial showing the benefit of artensuate that was published
in 2010,21 shortly before FEAST. We call on WHO to urgently
reassess the evidence for bolus fluid resuscitation and revise its
guidelines in accordance with this assessment.
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Table
Table 1| Risk of death among participants in the Fluid Expansion as a Supportive Treatment (FEAST) trial with the application of different
definitions of paediatric shock to admission data
Estimated annual No
of excess deaths in
Absolute risk difference
(95% CI)
Mortality among FEAST participants (%)Definition of shock
No bolus (control arm)Bolus (saline or albumin)Overall (all arms)
sub-Saharan Africa if
boluses given*
FEAST inclusion criteria
33 0003.3% (1.2 to 5.3)76/1044 (7)221/2097 (11)297/3141 (10)Total
14 5003.4% (0.9 to 5.9)34/593 (6)110/1202 (9)144/1795 (8)With malaria
16 0003.7% (0.3 to 7.1)38/446 (9)108/884 (12)146/1330 (11)Without malaria
WHO Emergency Triage Assessment and Treatment
1 80028% (3 to 53)3/15 (20)24/50 (48)27/65 (42)Total
1 30015% (−16 to 47)2/9 (22)12/32 (37)14/41 (34)With malaria
3 10065% (42 to 87)0/5 (0)11/17 (65)11/22 (50)Without malaria
American College of Critical Care Medicine cold shock (with two signs)
14 3004.5% (1.5 to 7.4)42/537 (8)147/1196 (12.3)189/1733 (11)Total
8 9004.4% (1.1 to 7.7);19/334 (6)76/753 (10)95/1087 (9)With malaria
9 9005.2% (−0.3 to 10.7)22/202 (11)70/435 (16)92/637 (14)Without malaria
Paediatric Advanced Life Support (2010) compensated shock
26 3003.9% (0.5 to 7.2)57/537 (11)161/1113 (15)218/1650 (13)Total
12 0003.4% (−0.4 to 7.2)27/325 (8)80/684 (12)107/1009 (11)With malaria
11 3006.0% (0.1 to 11.8)26/207 (13)78/421 (19)104/628 (17)Without malaria
* Per 1 million paediatric admissions with shock, using relative increase of 1.45 from overall trial result.
NB: There are 16 children with missing malaria results who are not included in the with/without malaria calculations.
FEAST criteria: History of fever or axillary temperature >37.4°C or <36°C with impaired consciousness (prostration or coma) or respiratory distress. plus ≥1 of
the following: capillary refill time >2 s, lower limb temperature gradient, weak pulse, tachycardia (heart rate >180 (<12 months), >160 (12 months-5 years), >140
(>5 years)).
WHO Emergency Triage Assessment Treatment criteria: The presence of cold hands or feet with capillary refill time longer than 3 seconds and a weak, fast pulse.
ACCM cold shock (with two signs): Axillary temperature >37.4°C or <36°C) plus ≥2 of: prostration/coma or Blantyre coma score <5, capillary refill time >2 s, weak
pulse, increased temperature gradient.
PALS (2010) compensated shock: Two of the following: tachycardia (see FEAST criteria for definition), increased temperature gradient, capillary refill time >2 s,
weak pulse.
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